Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004266 · ClinicalTrials.gov registry record · Phase 3
Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
NCT00004266 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 160 participants.
The verdict
NCT00004266, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
Interventions
- DRUG Nifedipine
- DRUG Simvastatin
- DRUG Lisinopril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 1993-08 |
| Est. Completion | 1999-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004266
The ClinicalTrials.gov registry entry for NCT00004266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nifedipine is the first listed.
NCT00004266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004266 about?
NCT00004266 is a clinical study titled "Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes". OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and va...
What is the current status of trial NCT00004266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 1993-08. Estimated completion is 1999-07.
What interventions are being tested in trial NCT00004266?
The interventions under investigation include: Nifedipine (DRUG), Simvastatin (DRUG), Lisinopril (DRUG).
Who is sponsoring clinical trial NCT00004266?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.